Patents by Inventor Kenneth N. Raymond

Kenneth N. Raymond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12268678
    Abstract: Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: April 8, 2025
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Rebecca J. Abergel, Taylor A. Choi, Kenneth N. Raymond, David K. Shuh
  • Patent number: 11684614
    Abstract: Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 27, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Rebecca J. Abergel, Taylor A. Choi, Kenneth N. Raymond, David K. Shuh
  • Patent number: 11648241
    Abstract: Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: May 16, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Rebecca J. Abergel, Taylor A. Choi, Kenneth N. Raymond, David K. Shuh
  • Patent number: 11617743
    Abstract: Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: April 4, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Rebecca J. Abergel, Taylor A. Choi, Kenneth N. Raymond, David K. Shuh
  • Publication number: 20220152003
    Abstract: Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent.
    Type: Application
    Filed: February 4, 2022
    Publication date: May 19, 2022
    Inventors: Rebecca J. Abergel, Taylor A. Choi, Kenneth N. Raymond, David K. Shuh
  • Publication number: 20210283115
    Abstract: Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.
    Type: Application
    Filed: September 5, 2017
    Publication date: September 16, 2021
    Inventors: Rebecca J. Abergel, Taylor A. Choi, Kenneth N. Raymond, David K. Shuh
  • Patent number: 10352938
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: July 16, 2019
    Assignee: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
  • Patent number: 9556122
    Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 31, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kenneth N. Raymond, Jide Xu, Evan G. Moore, Eric J. Werner
  • Publication number: 20160320399
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.
    Type: Application
    Filed: February 25, 2016
    Publication date: November 3, 2016
    Inventors: Nathaniel G. BUTLIN, Kenneth N. RAYMOND, Jide XU, Anthony D'ALEO
  • Patent number: 9439984
    Abstract: The invention provides macrocycles useful in chelating metal ions, particularly radionuclides, to provide metal ion complexes. The invention also provides methods of using the compounds and complexes of the invention, such as in therapeutic and diagnostic applications.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 13, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kenneth N. Raymond, Jide Xu, Tiffany A. Pham
  • Patent number: 9273059
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: March 1, 2016
    Assignee: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
  • Publication number: 20150157746
    Abstract: The invention provides macrocycles useful in chelating metal ions, particularly radionuclides, to provide metal ion complexes. The invention also provides methods of using the compounds and complexes of the invention, such as in therapeutic and diagnostic applications.
    Type: Application
    Filed: March 14, 2013
    Publication date: June 11, 2015
    Inventors: Kenneth N. Raymond, Jide Xu, Tiffany A. Pham
  • Patent number: 8729258
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: May 20, 2014
    Assignee: The Regents of the University of California
    Inventors: Kenneth N. Raymond, Todd M. Corneillie, Jide Xu
  • Publication number: 20140039169
    Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 6, 2014
    Inventors: Kenneth N. RAYMOND, Jide Xu, Evan G. Moore, Eric J. Werner
  • Patent number: 8557601
    Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: October 15, 2013
    Assignee: The Regents of the University of California
    Inventors: Kenneth N. Raymond, Jide Xu, Evan G. Moore, Eric J. Werner
  • Patent number: 8551453
    Abstract: The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention.
    Type: Grant
    Filed: December 29, 2004
    Date of Patent: October 8, 2013
    Assignee: The Regents of the University of California
    Inventors: Kenneth N. Raymond, Stephane Petoud, Jide Xu
  • Publication number: 20120329174
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.
    Type: Application
    Filed: April 30, 2012
    Publication date: December 27, 2012
    Applicant: The Regents of the University of California
    Inventors: Kenneth N. RAYMOND, Tood M. CORNEILLIE, Jide XU
  • Publication number: 20120214843
    Abstract: The invention provides for a method for treating a subject in need of such treatment comprising administering a therapeutically effective amount of one or more pharmaceutical compositions comprising a 1,2-HOPO chelating agent and a 3,2-HOPO chelating agent to a subject in need of such treatment. The use of both 1,2-HOPO and a 3,2-HOPO chelating agents in combination is more effective than using only one chelating agent alone. The invention is especially useful when practiced on a subject that has been exposed to, have been in contact with, or contaminated by one or more known or unknown actinides and/or lanthanides, or a mixture thereof.
    Type: Application
    Filed: November 8, 2011
    Publication date: August 23, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Patricia W. Durbin-Heavey, Leonore Frances Heavey, Kenneth N. Raymond, Rebecca J. Abergel, David K. Shuh
  • Publication number: 20120214253
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.
    Type: Application
    Filed: August 24, 2010
    Publication date: August 23, 2012
    Applicant: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Kenneth N. Raymond, Jide Xu, Anthony D'Aleo
  • Patent number: 8173800
    Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: May 8, 2012
    Assignee: The Regents of the University of California
    Inventors: Kenneth N. Raymond, Todd M. Corneillie, Jide Xu